Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Rating) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 1,290,000 shares, an increase of 42.8% from the June 30th total of 903,300 shares. Based on an average daily volume of 498,900 shares, the short-interest ratio is presently 2.6 days. Approximately 5.8% of the shares of the stock are short sold.
Assembly Biosciences Trading Down 2.9 %
NASDAQ:ASMB opened at $2.01 on Tuesday. The firm has a 50 day moving average of $2.06 and a 200-day moving average of $1.88. Assembly Biosciences has a 1 year low of $1.32 and a 1 year high of $3.94.
Assembly Biosciences (NASDAQ:ASMB – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.01. On average, equities research analysts predict that Assembly Biosciences will post -1.95 earnings per share for the current year.
Analyst Upgrades and Downgrades
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Deep Track Capital LP bought a new position in Assembly Biosciences in the 4th quarter worth approximately $6,990,000. Candriam Luxembourg S.C.A. grew its holdings in Assembly Biosciences by 25.1% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 1,838,221 shares of the biopharmaceutical company’s stock worth $4,283,000 after acquiring an additional 369,375 shares during the period. Acadian Asset Management LLC grew its holdings in Assembly Biosciences by 13.9% during the 4th quarter. Acadian Asset Management LLC now owns 1,608,760 shares of the biopharmaceutical company’s stock worth $3,746,000 after acquiring an additional 196,033 shares during the period. Assenagon Asset Management S.A. grew its holdings in Assembly Biosciences by 1,422.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 684,846 shares of the biopharmaceutical company’s stock worth $1,438,000 after acquiring an additional 639,859 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Assembly Biosciences by 54.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 553,428 shares of the biopharmaceutical company’s stock worth $1,289,000 after acquiring an additional 194,113 shares during the period. Institutional investors own 52.63% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc, a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
- Get a free copy of the StockNews.com research report on Assembly Biosciences (ASMB)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.